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Abstract
OBJECTIVE: To review the interactions between
herbs and widely used drugs and summarize the as-
sociated experimental methods.
METHODS: Definite herb-drug interactions were
obtained by searching PubMed, other large over-
seas databases and summarizing new researches
from China. We summarize some methods to as-
sess the interaction between herbs and drugs in-
volving microsomal, cell culture and animal experi-
ments, and clinical trials, classifying this method as
single ingredient herbs, crude herb extracts, and
herbal formulae.
RESULTS: Many herbs interact with drugs through
a complex cytochrome P450 and/or P-glycoprotein
mechanism. Herb-induced enzyme inhibition and/
or induction may result in enhanced and / or de-
creased plasma, tissue, urine and bile drug concen-
trations, leading to a change in a drug's pharmaco-
kinetic parameters and resulting in the improper
treatment of patients and potentially severe side ef-
fects. Use of an appropriate method for compre-
hensively assessing herb-drug interactions can min-
imize clinical risks. Different methods were used by
researchers to assess the pharmacological changes
of drugs in vivo and in vitro and the mechanisms of
the interactions from microsomal, cell culture and
animal experiments, and clinical trials are discussed
in this review.
CONCLUSION: Co-medication with herbs can re-
sult in changes in pharmacological effects of many
drugs. This review describes the assessment of sin-
gle-ingredient herbs, crude herb extracts, and herb-
al formulae. When choosing a research method to
investigate herb-drug interactions, the properties
of the drugs and herbs should be considered.
© 2016 JTCM. All rights reserved.
Key words: Herb-drug interaction; Metabolism; Cy-
tochrome P-450 enzyme system; P-glycoprotein;
Review
INTRODUCTION
Herbal medicines have been used for more than 5000
years.1 However, in ancient times only single herbs
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were ingested.2 Today, herbal medicines are frequently
used, especially among women and patients with
chronic diseases.3 Approximately 15%-20% of individ-
uals taking prescription medications use herbal supple-
ments. However, fearing censure, they may not be
forthcoming to their physicians about their personal
use of herbal medicines, even if they experience severe
side effects.4-6
The interactions between herbs or dietary supplements
and drugs requires attention, especially for the elderly,
frail, or those taking multiple medications for chronic
diseases.7 Several important foods such as grapefruit
juice, and herbals such as Yinxingye (Ginkgo biloba. L)
have been reported to cause clinically significant ad-
verse drug reactions.8 Ginkgo products administered
concurrently with aspirin, warfarin (Coumadin), or ti-
clopidine (Ticlid) interact and can cause bleeding. Ad-
ditionally, St. John's wort (SJW)9 and antidepressants
administered together cause side effects such as gastro-
intestinal disturbances and allergic reactions.
The safety of herbs is mostly dependent on empirical
experience, but these observations are not always effec-
tive at limiting side effects. Sometimes, the first signs
of adverse effects take a long time to be recognized or
they are recognized even after the patient has stopped
using the herbs. Additionally, the ingestion of herbs is
easily overlooked, therefore more publicly available in-
formation should be provided.10 Extensive research into
herb-drug interactions should be conducted to provide
more information for patients and health care providers.
A search of PubMed into the study of herb-drug inter-
actions revealed that the choice of methods can have a
profound impact on the experimental results, primarily
because of the complex mechanisms involved. Herein,
we summarize the methods used to study the interac-
tions of individual herbal ingredients, crude herb ex-
tracts, and herbal formulas with drugs, and their mech-
anisms of action, and classify the experiments accord-
ing to the different models employed.
Mechanisms of herb-drug interactions
Drugs usually contain single chemical entities, while al-
most all herbal products contain mixtures of pharmaco-
logically active constituents. As such, herb-drug interac-
tions could occur more frequently than drug-drug in-
teractions,11 and the mechanism of herb-drug interac-
tions may be more complex. In vitro and in vivo stud-
ies, clinical trials and case reports demonstrated that
herbal agents, particularly SJW and Yinxingye (Ginkgo
biloba. L), interact with several prescribed medications
and affected their pharmacokinetic profiles. In most
herb-drug interactions, the cytochrome P450 (CY-
P450) system and the efflux drug transporter P-glyco-
protein (P-gp) play an important role.1 More than half
of the herbs ingested likely interact with the CYP sys-
tem, which is also responsible for metabolizing many
medications that inhibit and induce drug metabo-
lism, and the P-gp, which is also important in herb
disposition.
Research suggests that the mechanisms regulating
herb-drug interactions often involve CYP isoforms. For
example, studies on SJW used various animal models
to study the different mechanisms involving CYP3A4,
CYP2C19, and P-gp. The results indicated that the in-
teractions observed in vivo with different drugs was
similar to those observed using animal models.12-17 The
relative abundance of the CYP isoforms are 30%
CYP3A4, 13% CYP1A2, 7% CYP2E1, 4% CYP2A6,
2% CYP2D6, 20% CYP2C, and 1% CYP2B6 in hu-
man hepatic smooth endoplasmic reticulum where
50% of drug metabolism occurs via CYP3A4, followed
by 25% CYP2D6 and 20% CYP2C.18 In these studies,
CYP3A4 mainly mediated the drug interaction via the
CYP system, especially for SJW.
The mechanisms of herb-drug interactions also involve
different transport proteins, especially P-gp. P-gp, an
ATP (adenosine triphosphate)-dependent membrane
transporter,19 is expressed in a broad range of tissues in-
cluding the colon and intestinal mucosa, blood-testis
capillary epithelial cells, liver cells, the adrenal gland
and kidney proximal tubules. It works to decrease the
oral absorption, intracellular concentration and bio-
availability of xenobiotics.20,21 In the ATP binding cas-
sette (ABC) family, P-gp is the largest subgroup, which
also includes multidrug resistance-associated protein
P1 (MRP1) and ABCG2.22 Most of the interactions be-
tween herbs and drugs is P-gp-mediated, while interac-
tions with other drugs, such as baicalein, involves
MRP1, MRP2 and ABCG2.23
In vitro research studies were conducted to assess the ac-
tivity of the enzymes involved by determining the cyto-
plasm or the microsome involvement, and these were
sometimes followed by in vivo studies that assessed the
herb-drug interactions. Not all studies investigate the
herb-drug interactions at the metabolism level, but still
provide useful information. For example, Aurantium
caused enhancement of gastrointestinal motility at the
peak plasma concentrations of amiodarone.24 Addition-
al studies may be required to determine the mecha-
nisms involved.
Summary of the experimental methods used to study
the interactions of single component herbs with
drugs
Studying single herb components can provide specific
information about the nature of the herb and its mech-
anism of interaction. Research on Chuanxinlian (Her-
ba Andrographitis Paniculatae) extract and its major
component, andrographolide, which interacts with the-
ophylline, showed that certain components other than
andrographolide inhibited theophylline elimination in
rats, and that the mechanism involved androgra-
pholide-induced induction of CYP1A2.25 Thus, studies
of the isolated herb component provided useful infor-
mation on its mechanism of action. A total of 28 single
herb components known to interact with drugs are list-
ed in Table 1. The information has come from clinical
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trials and animal and cell studies. Animal models and
cell culture experiments are commonly used to study
drug interactions. Animal models were used to investi-
gate the interactions between baicalin and rosuvastatin,26
resveratrol and pyrogallol,27 Tanshinone ⅡA (TⅡA)
and warfarin,28 ferulic acid and clopidogrel,29 baicalin
and midazolam,30 rutaecarpine and theophylline,31 sino-
menine and paeoniflorin,32 and curcumin and losar-
tan.33 Cell culture experiments were conducted to
study the interactions between andrographolide, the-
ophylline and dexamethasone,34,35 triptolide and cisplat-
in,36 salvianolic acid B and rifampicin,37 silibinin, trazo-
done and lasalocid,38,39 trichosanthin and imatinib.40
and solamargine and epirubicin.41
Research using animal models usually included analysis
of the drug's pharmacokinetic parameters. For exam-
ple, the end of the maximum plasma concentration
(Cmax) of ferulic acid was significantly increased by
74.3% when clopidogrel was co-administered. Addi-
tionally, the peak time (Tmax) of ferulic acid was 3 and
3.76 times slower and the area under the concentra-
tion-time curve (AUC) was increased by 63.5% and
79.7% when co-administered with Honghua (Flos Car-
thami) or clopidogrel, respectively, compared with feru-
lic acid administration alone.29 Studies on baicalin,83 ru-
taecarpine,31 sinomenine32 and curcumin100 were also
conducted using this method. Other methods have
been used to assess herb-drug interactions. For exam-
ple, the measurement of glutathione-S-transferase
(GST), glutathione reductase and glutathione peroxi-
dase activity and the measurement of CYP1A1,
CYP1A2 and CYP2E1 enzymatic activity were used to
assess the interaction between resveratrol and pyrogal-
lol.27 Another example is the study of the active compo-
nent of Danshen (Radix Salviae Miltiorrhizae), TⅡA,
which affects warfarin pharmacokinetics and acceler-
ates warfarin metabolism. Warfarin and its metabolites
were detected in high concentrations in urine and
blood collected from rats that were orally dosed with
warfarin together with TⅡA, but when warfarin was
orally administrated alone to rats, a low level of warfa-
rin and only a few of its metabolites were detected in
urine or blood. This could be because water-soluble so-
dium TⅡA sulfonate displaces warfarin from the war-
farin-human serum albumin complex, resulting in an
increase of free warfarin concentration in blood.28
Cell culture experiments were used by some investiga-
tors in order to study pharmacokinetics as exemplified
by the investigation into the interaction of trazodone
and silibinin.39 Alternatively, studies of the growth rate
inhibition in K562 cells showed that trichosanthin has
a synergistic effect with imatinib to induce K562 cell
growth arrest, down-regulate p210(Bcr-Abl) in a time- and
dose-dependent manner, reduce its downstream sig-
nals, and stimulate the effect of tyrosine kinase inhibi-
tion by the human chronic myelogenous leukemia
(CML) cell line, K562 (Ph+).40 Silybin was investigated
using cell metabolism, cellular protein content, andStu
dy
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cell membrane integrity.38 Another study assessed
HepG2 cell proliferation and CYP1A2 and CYP3A4
mRNA expression in the presence or absence of rifam-
picin, which interacted with salvianolic acid B.37 The
same study design was used for triptolide36 and an-
drographolide.35
Microsomal experiments have also been used to investi-
gate herb-drug interactions, which involve using
pooled human liver microsomes and rat liver micro-
somes. For example, a study conducted using pooled
human liver microsomes indicated that the synergistic
effect between beauvericin and ketoconazole on anti-
fungal activity may occur through a pharmacodynamic
function.85 Studies on mollugin91 and TⅡA99 also used
the microsomal method.
Animal models have been combined with microsomal
experiments or cell culture experiments to investigate
drug interactions. Quercetin,93 californine and proto-
pine,86 scutellarin95 and silibinin98 were studied using a
combination of animal models and microsomal experi-
ments. The pharmacokinetics of quercetin and scutella-
rin were investigated to assess their interaction with pi-
oglitazone and phenacetin. Additionally, metabolite for-
mation rates were detected.86 Determination of the se-
rum aminotransferase activity, bilirubin content and
histological analysis indicated that silymarin prevented
CYP2E1-and CYP1A2-mediated free radical genera-
tion, and thereby modulated the effect of individual
and combined exposure to rifampicin and/or pyrogal-
lol. Silymarin also restored GST, glutathione reductase
and glutathione peroxidase levels in pyrogallol- and/or
rifampicin-induced hepatotoxicity, which led to the
scavenging of free radicals.98 The pharmacokinetics of
Schisandra lignans97 and quercetin93 were studied using
a combination of animal models and cell culture experi-
ments.
The in situ intestinal perfusion model and the Caco-2
cell lysate model were used to study the interaction be-
tween Baicalein and acetaminophen, ( −)-epicatechin,
piperine and curcumin. All the four selected com-
pounds produced dose-dependently inhibited Baicalein
glucuronidation and sulfation.30 Scoparone was studied
using primary hepatocytes, hepatoma cells and pooled
human liver microsomes. The results of this study indi-
cated that Scoparone induced CYP2B6 expression.96
Research has also been conducted on the interactions
between drugs and single herb components. Cell cul-
ture experiments have been performed on quercetin
(an extract of gingko leaves) and isorhamnetin [a total
flavone of Shaji (Fructus Hippophae)]. After coadminis-
tration with each other to rats, the Cmax, AUC0–72 h, and
AUC0 – ∞ of both isorhamnetin and quercetin signifi-
cantly increased compared with single administration 90
Herbs are composed of many components. All studies
reviewed thus far have investigated the interaction of a
single herb component or the single herb, but there has
been little information about the interactions between
herbal ingredients. For example, studying gingko leaf
extract and its interaction with drugs might encounter
unknown challenges because of the potential interac-
tions between two components of the herb, quercetin
and isorhamnetin. Similar issues exist in other herb
products where there may be interactions between mul-
tiple ingredients in one herb formula.
Summary of the experimental methods used to study
the interactions of crude herbal extracts with drugs
A single herbal preparation may contain more than
100 components, all of which may have some biologi-
cal activity. The herbs can potentially mimic, increase,
or inhibit the effects of co-administered drugs through
simultaneous effects on the same drug targets.101 Thus,
the interaction between a drug and the crude extract of
one herb will likely be complex, and one herb may be
the substrate for multiple enzymes. Researchers used
different models to show the effects and mechanisms
of herb-drug interactions. A crude extract of 38 herbs
was shown to interact with drugs by using different
models (Table 1). These models include animal experi-
ments, cell culture experiments, microsomal experi-
ments and clinical trials. Animal experiments account-
ed for the largest proportion, while cell culture experi-
ments and microsomal experiments were used less than
clinical trials.
Examples of single methods and multiple methods
used to assess the interactions of crude herbal
extracts with drugs
Drug-herb interactions may be studied using only one
method. Clinical trials were used to show the interac-
tion of Renshen (Radix Ginseng)67 and cranberry46 with
midazolam and warfarin, respectively. Animal models
are commonly used to detect changes in pharmacoki-
netic parameters. For example, using both rat and rab-
bit models, co-administration of Hibiscus sabdariffal
extract (HSE) with hydrochlorothiazide (HCT) in-
creased and prolonged the AUC, Cmax, Tmax, the elimina-
tion half-life (T1/2) of HCT.72 Xiaohuixiang (Fructus
Foeniculi),74 Fucus vesiculosus extract,53 Gegen (Radix
Puerariae Lobatae)55 and S. frutescens72 were also stud-
ied using animal models.
Often, drug-herb interactions are studied using multi-
ple methods, which most frequently involve animal
models combined with in vitro studies. A combination
of animal models and microsomal experiments were
used for studies of Gancao (Radix Glycyrrhizae), Hong-
hua (Flos Carthami), tenryocha, and rooibos tea. After
an aqueous decoction of Glycyrrhiza uralensis was ad-
ministered, the AUC of lidocaine was reduced by 41%,
its clearance (CL) increased by 59% and its T1/2 de-
creased by 39% . The mechanism involved the ability
of Gancao (Radix Glycyrrhizae) to activate the nuclear
receptor, PXR, which is known to induce CYP3A.54
Honghua (Flos Carthami) significantly inhibited
CYP2D6 in vitro and in vivo, resulting in increases in
the AUC0-inf, Cmax, and T1/2 of metoprolol because of a
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decrease in CYP2D6 catalyzed metabolism.68 After
combining tenryocha and rooibos tea, the AUC0-inf and
the Cmax of midazolam (MDZ) (20 mg/kg) were re-
duced by more than 60% , suggesting that hepatic
CYP3A and CYP2C11 might not be affected by the
teas.82 A combination of animal models and other in vi-
tro studies was also used, including gut sac studies (ex
vivo) and cell culture experiments to investigate the in-
teractions of Ziran (Cuminum cyminum L.) and
Huajuhong [Citrus grandis (L.) Osbeck] peel. The re-
sults from the ex vivo gut sac study suggested that the
interactions might not be associated with intestinal
P-gp. Additionally, co-administration of Huajuhong
[Citrus grandis (L.) Osbeck] peel significantly increased
the AUC0-t and Cmax of cyclosporine and the AUC0-t and
Cmax of tacrolimus.59 The compound 3',5-dihydroxyfla-
vone 7-O-β-D-galacturonide-4'-O-β-D- glucopyrano-
side (CC-I), which is an aqueous extract of Ziran
(Cuminum cyminum L.), enhanced the AUC of ri-
fampin by 53% and its Cmax by 35% by increasing the
rate of mucosal-to-serosal transfer of rifampin, but its
Tmax remained unchanged. The altered bioavailability
profile of rifampin was caused by the enhancing effect
of this glycoside, and it is speculated that the mecha-
nism may be related to P-gp and CYP3A4, because ri-
fampin is a well-known inducer of P-gp and CYP3A4.33
A combination of cell culture and microsomal experi-
ments was used to study Tongguanteng (Radix seu Her-
ba Marsdeniae Tenacissimae) extract. Pooled human liv-
er microsomes and the human hepatoma cell line
HepG2 was used, and the results showed that concomi-
tant use of Tongguanteng (Radix seu Herba Marsdeniae
Tenacissimae) extract with gefitinib significantly re-
duced CYP2D6 and CYP3A4 mRNA and protein ex-
pression in human hepatoma HepG2 cells.73
Examples of the interactions of some common herbs
with drugs and the associated methods used for
investigations
Certain commercially valuable herbs have been studied
by multiple researchers using different models. Exam-
ples include SJW [Guanyejinsitao (Hypericum perfora-
tum L.)], Sutherlandia frutescens, Ginkgo biloba ex-
tract, Danshen (Radix Salviae Miltiorrhizae) extract,
Echinacea purpurea extract and Dasuan (Bulbus Allii).
The interactions of SJW with various drugs have been
extensively studied using clinical trials. SJW was shown
to interact with docetaxel (through CYP3A4),12
omeprazole (through CYP2C19),16 norethindrone
(through CYP3A),102 and digoxin (through P-gp)103 us-
ing clinical trials. Using a combination of animal mod-
els and an isolated perfused rat liver model, administra-
tion of the SJW extract resulted in a significant in-
crease in tolbutamide AUC and T1/2 and a significant
decrease in CL by altering CYP2C6 metabolism. There
was also a significant decrease in the dextrometho-
rphan AUC and T1/2 mediated by CYP2D2, and a sig-
nificant increase in the dextrorphan AUC and the dex-
tromethorphan CL. SJW extract administration also re-
sulted in a significant decrease in the AUC and T1/2,
and a significant increase in the CL of midazolam
(through CYP3A2) and in the AUC of 4-hydroxymid-
azolam.13 Additionally, using a combination of an ani-
mal model and an in situ single-pass intestinal 5-perfu-
sion model showed that the SJW pretreatment group
had a lower indinavir concentration in the liver than in
the intestine with a perfusion flow rate of 1 mL/min.14
A combination of the two methods was also used to ex-
amine the drug interactions for SJW extract. Human
plasma was used to simultaneously assess its interac-
tions with nifedipine and dehydronifedipine.15
Clinical trials were used to assess interactions from
GBE [Yinxingye (Ginkgo biloba L.)] extract with alpra-
zolam. Simultaneous administration of GBE extract
and alprazolam decreased the AUC, Cmax and Tmax. As al-
prazolam is a substrate of CYP3A4, these effects that
were likely mediated by modulating CYP3A4.75 A mi-
crosome model combined with an in vivo study indicat-
ed that the anticoagulation effects of warfarin were sig-
nificantly attenuated by co-treatment with GBE, and
the mechanism is CYP-mediated.80 Animal models are
commonly used alone to detect changes in drug phar-
macokinetic parameters, and also interactions between
herbs and drugs. For example, when GBE was adminis-
tered to rats, the hypotensive effect of nicardipine,
which is metabolized by CYP3A2 in rats, and the activ-
ity of liver glutathione S-transferase were significantly
reduced.75 Orally administered GBE or ethanol extract
did not affect the pharmacokinetics after intravenous
administration of nifedipine. The AUC and Cmax of
nifedipine and the absolute bioavailability of nifedip-
ine after oral administration were significantly in-
creased by simultaneous oral treatment with GBE.
GBE given orally to rats seems to inhibit CYP3A.8 The
GBE also interacted with theophylline, as observed by
its altered pharmacokinetic parameters.78
When Echinacea purpurea was co-administered with
darunavir, the clinical pathology of Caucasian HIV-in-
fected patients showed that there was little change in
the darunavir pharmacokinetic parameters. This phe-
nomenon was mediated by CYP3A4.51 When Echina-
cea purpurea was administered to healthy volunteers,
midazolam CL (hepatic and intestinal CYP3A) was sig-
nificantly increased by 34%, the AUC was significantly
reduced by 23% , and the oral availability was in-
creased. In contrast, the CL of oral midazolam was not
significantly altered. Echinacea dosing significantly re-
duced the clearance of oral caffeine (CYP1A2) by
26% , and the CL of oral tolbutamide (CYP2C9) by
11%, but this change was not considered to be clinical-
ly relevant because the 90% CIs were within the
80%-125% range.50
Research on Dasuan (Bulbus Allii) interactions in-
volved clinical trials. Dasuan (Bulbus Allii) was shown
to interact with dextromethorphan, alprazolam and
warfarin, and the interactions with dextromethorphan
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and warfarin were significant, but there were no signifi-
cant differences with alprazolam. The interactions be-
tween dextromethorphan and alprazolam were mediat-
ed by CYP2D6 and CYP3A4, respectively.104
Using a microsome model, a combination of Suther-
landia frutescens and midazolam was found to decrease
the MDZ CL by 40% and the affect was mediated by
CYP3A4/5.70 An animal model was also used to investi-
gate of the effects of Sutherlandia frutescens adminis-
tration. After 5 days of chronic exposure to Sutherland-
ia frutescens, there was a 45% and 51% decrease in the
AUC and Cmax values of nevirapine, respectively. The re-
duction in plasma concentration of nevirapine in a
dose-dependent manner after long-term treatment is
primarily because of enhanced metabolism catalyzed
by elevated levels of CYP3A2.71 Study of the Danshen
(Radix Salviae Miltiorrhizae) extract revealed that Dan-
shen (Radix Salviae Miltiorrhizae) did not change sig-
nificantly as a result of P-gp- and CYP3A-mediated in-
teractions because of the low in vivo exposure of its in-
hibitory components.105
When human albumin was used as a model, treatment
with 10, 25, or 50 μL Danshen (Radix Salviae Miltior-
rhizae) extract increased the free salicylate by 27.5% ,
39.3% and 58.8%, respectively. The ability of Dansh-
en (Radix Salviae Miltiorrhizae) to displace salicylate
from the protein-binding site was also investigated us-
ing a fluorescence polarization digoxin immunoassay.
No significant change in free Danshen (Radix Salviae
Miltiorrhizae) concentrations were noted when the free
digoxin-like activity was measured at salicylate concen-
trations less than 100 mg/mL. However, when the salic-
ylate concentrations were more than 150 mg/mL, the
free Danshen (Radix Salviae Miltiorrhizae) concentra-
tions was significantly decreased.48
The examples provided for the six herbs were studied
using different methods to identify the interactions me-
diated by single or multiple enzymes. The studies de-
scribed above used crude herb extracts which may com-
plicate the studies of the interaction when only one
herb and one drug are involved. Studying the individu-
al components that are related to the herb-drug interac-
tion, and determining the mechanism of action for a
specific component may provide more conclusive infor-
mation. In summary, the interactions between the in-
gredients of the herbal formulae themselves should also
be considered.
Interactions between herbal formulae and drugs
Herbal formulae usually include many herbs, and be-
cause interactions exist between the single herb compo-
nents, we can hypothesize that there are likely interac-
tions between the components of every herbal formula.
The interactions between the ingredients of Huanglian-
jiedu Tang (HLJDT) have been studied. Compared
with the control group, after oral administration of Ra-
dix scutellariae extract (188 mg/kg baicalin and 47 mg/
kg wogonoside) and HLJDT (193 mg/kg baicalin and
43 mg/kg wogonoside), the AUC of baicalin and
wogonoside was decreased by 36% and 47% , respec-
tively. The Cmax was also decreased by 4% for baicalin,
but increased by 20% for wogonoside, and the T1/2 was
increased by 14% for both.106 The interactions of Sha-
oyaogancao Tang were studied to assess the pharmaco-
kinetic parameters of albiflorin and paeoniflorin.
When the active components of Radix paeoniae alba
were administered with Shaoyaogancao Tang, the
AUC0-inf of albiflorin and paeoniflorin was decreased by
36% and 48%, respectively, compared to co-adminis-
tration of the single herb peony decoction, and the Cmax
was decreased by 8.3% and 9.6%, respectively, but the
T1/2 and Tmax showed no significant changes.107
Animal models, which were used most frequently in
the above studies, generally provide information about
the pharmacokinetic parameters of drugs. PHY906, a
Traditional Chinese Medicine formula that has been
used for the last 1,800 years to treat distressing condi-
tions of the gastrointestinal tract, was studied using an
animal model. Murine Colon 38 cells were transplant-
ed subcutaneously into four- to six-week-old female
BDF1 mice, and after the treatments were adminis-
tered, tumor tissue was removed, divided and frozen
until the total RNA was isolated or histological analysis
was performed. The results indicated that PHY906
and CPT-11 alone induced significant alterations in all
evaluated tissues. However, the distinct alterations in
the tumor, liver and spleen were reversed when the
compounds were administered simultaneously with
prevalent induction of pro-apoptotic and proinflamma-
tory pathways that may favor tumor rejection. Current-
ly, the mechanism and parameter values are not
known.108
CONCLUSIONS
Implications of herb-drug interactions
Clinical implications of herb-drug interactions de-
pends on a variety of factors that are related to co-ad-
ministered medicine (species, dose, dosing regimen, ad-
ministration route, pharmacokinetic and therapeutic
range) and have been previously reported.109 Before de-
signing an experiment, many factors should be taken
into consideration. Herein, we comprehensively re-
viewed the available information on herb-drug interac-
tions, and summarized and classified the general study
designs based on the object of the experiment.
Generally, in vitro studies, microsomal experiments
and cell culture experiments were used in most studies.
In vivo studies most often involved animal experi-
ments, and clinical trials were used less frequently.
Many studies included a combination of in vivo and in
vitro studies, and it was common that in vivo studies
were combined with microsomal experiments or cell
culture experiments. Results obtained from using a
combination of methods likely better reflect metabo-
lism and transport mechanisms.
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Some special phenomena should be highlighted. For
example, simultaneous administration of high-dose
and low-dose andrographolide and theophylline could
result in conflicting results for the AUC.25 Varying the
dose could have a more significant influence on the
pharmacokinetic parameters than a single dose. Howev-
er, when a single-dose of Fucus vesiculosus extract (575
mg/kg, p.o.) and amiodarone (50 mg/kg, p.o.) were
co-administered by oral gavage, the AUC0-t, AUC0-inf
and Cmax of amiodarone was decreased by 30%, 27%,
and 55.4% , respectively. After pretreatment for 14
days, there were only minor changes in amiodarone pa-
rameters.53 Not all studies were useful for identifying
the mechanism, and many articles speculated on the
mechanism based on the results. CYP and P-gp are the
most common enzymes that mediate herb-drug interac-
tions, but other enzymes are also mentioned. For exam-
ple, it was found that curcumin could significantly in-
crease the absorption of baicalein via MRP1-, MRP2-
and breast cancer resistance protein (BCRP)- mediated
transport.30 Herb-drug interactions can also be mediat-
ed via other mechanisms. For example, Zhiqiao (Fruc-
tus Aurantii Submaturus) peel increased the rate of gas-
trointestinal motility, resulting in altered pharmacoki-
netic parameters of amiodarone.82
Key points to consider when identifying herb-drug
interactions
Selection of the method and the details of the experi-
mentation are the key points for a successful experi-
ment. A successful experiment does not completely
mimic previous research, but should consider the na-
ture of the drug itself and the purpose of the study,
which should be based on an extensive literature review.
The nature of the drug should determine how best to
assess its efficacy. For example, because the administra-
tion of GBE for one month may improve peripheral
diseases and dementia, the time of GBE treatment
should be considered in the experimental design as it
may be useful to administer GBE for more than 4
weeks to obtain a clinically relevant period for study.110,111
Warfarin is known to produce an anticoagulant effect,
which is needed for the carboxylation of several blood
coagulation proteins, and therefore, a few days are nec-
essary after administration of warfarin for an effect to
be observed.87 Thus, when studying warfarin in rats,
the (S)-form and (R)-form of warfarin should be ad-
ministered on days 3 to 5 before the first sampling be-
cause of the time lag after administration between the
maximum plasma warfarin concentration and its anti-
coagulant action.112 The nature of each herb is different
and certain experimental methods are necessary when
studying the pharmacological properties of the drug.
Additionally, the results should be obtained according
to the study aims. For example, the interaction of GBE
and theophylline was studied by administering theoph-
ylline orally and intravenously in order to distinguish
between hepatic and intestinal metabolism. The results
showed there was an equivalent reduction in the AUC
of theophylline, indicating that oral pretreatment with
GBE induced the hepatic metabolism of theophylline
but not its intestinal metabolism.79
A successful experiment should choose a method that
can serve its required purposes. When studying drug-
herb interactions, the method used may be the most
important factor to consider because choosing different
models might affect the results. For example, in clinical
treatment, the effect of GBE on the hepatic CYP activi-
ty (CYP1A2, CYP2D6, CYP2E1, and CYP3A4) in pa-
tients is different from that obtained from treatment of
12 healthy volunteers.113,114 The models described in
this review include microsomal models, cell culture, an-
imal models and clinical trials. Animal models were
used by most groups, and clinical trials were used by
only a few groups. Most microsome studies were com-
bined with in vitro or in vivo studies to better evaluate
the herb-drug interactions. The microsomal studies
typically included human liver microsomes, rat liver
microsomes, or other tissues and organs (intestine and
kidney). When combined with in vivo studies, micro-
some experiments were usually used to assess the activi-
ty of the herbs on the enzymes by measuring the rate
of drug metabolism, and to relate any changes ob-
served to a concentration-inhibition curve. Similar to
the microsomal experiments, cell culture was used to
assess mRNA and protein expression after herb-drug
treatment. Many kinds of cells were used in these stud-
ies including hepatocytes, Caco-2 cells, HepG2 cells,
human normal urothelial cells, six urothelial cancer cell
lines (RT112, RT4, KK47, TCCsup, EJ and J82) and
a PC3 prostate cancer cell line, primary hepatocytes,
hepatoma cells, and K562 cells. Cell culture experi-
ments were also combined with in vivo studies. For ex-
ample, Caco-2 cells and MDCKII/MDR1-MDCKII
cell culture was combined with an in vivo study to vali-
date whether isorhamnetin interacted with P-gp, and a
pharmacokinetics study was conducted in rats.89 In an-
other study, an in vitro screen using Caco-2 cell mono-
layers were performed to investigate the influence of
various components (quercetin, hesperetin, piperine,
curcumin and naringenin) on the transport of irinote-
can, and it was followed by an in vivo study.92
In summary, both patients and healthy people should
pay attention to the possible complications of herb-
drug interactions because of the complex ingredients,
and the universal applications of herbal products.
Their interaction mechanisms are complex, and possi-
ble side effects are becoming more commonplace. The
method chosen should play a decisive role in designing
the studies to assess these herb-drug interactions.
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